Tips from the Journals of the American Society for Microbiology

June 19, 2007

Needle-free Vaccine May Protect Against C. Difficile Infection

Researchers from the U.S. and abroad have developed a transcutaneous (needle-free) vaccine delivered through a patch applied to the skin that protects mice from C. difficile infection. They report their findings in the June 2007 issue of the journal Infection and Immunity.

Clostridium difficile is the leading cause of nosocomial diarrhea worldwide with more than 300,000 cases reported each year in the U.S. alone. The recent emergence of a new highly virulent strain has increased the need for effective preventative treatment methods.

Toxins A and B are the two major virulence factors expressed by C. difficile. Toxin A initiates infection allowing toxin B to access underlying cells. In the study researchers developed a vaccine including anti-toxin A antibodies and transcutaneously immunized mice, some also with the cholera toxin and some without, over a period of 42 days. Mice immunized with both C. difficile toxin A and cholera toxin displayed prominent immune responses to both toxins and blood from immunized mice was capable of neutralizing C. difficile toxin A in a cell culture test.

"Our results suggest that transcutaneous immunization with C. difficile toxin A may be a feasible immunization strategy against C. difficile, an important cause of morbidity and mortality against which current preventative strategies are failing," say the researchers.

(C. Ghose, A. Kalsy, A. Sheikh, J. Rollenhagen, M. John, J. Young, S.M. Rollins, F. Qadri, S.B. Calderwood, C.P. Kelly, E.T. Ryan. 2007. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infection and Immunity, 75. 6: 2826-2832).




Respiratory Tract Immunization May Protect Against Ebola Virus

A topical respiratory tract vaccine tested for the first time in a primate model may protect against Ebola virus infection. Researchers from the National Institutes of Health, Bethesda, MD and the Centers for Disease Control, Atlanta, GA report their findings in the June 2007 issue of the Journal of Virology.

Ebola virus is a highly contagious form of severe hemorrhagic fever with a mortality rate of up to 88% in humans. Because it can be transmitted by contact and aerosol route, it is also considered to be high risk for use as a biological weapon. With the respiratory route as the common portal of pathogen entry, intranasal vaccines may prove vital in preventative therapies.

In the study researchers developed a vaccine incorporating the human parainfluenza virus type 3 (HPIV3), a common pediatric respiratory pathogen, and administered it by respiratory route to rhesus monkeys. Some monkeys were immunized once and others twice, then all were challenged with a highly lethal dose of the Ebola virus. Results showed that a single immunization protected 88% of the animals against severe hemorrhagic fever and death, while all those receiving two doses not only survived but were symptom free and no detectable Ebola virus was found in the bloodstream.

"These data illustrate the feasibility of immunization via the respiratory tract against the hemorrhagic fever caused by Ebola virus," say the researchers. "To our knowledge, this is the first study in which topical immunization through respiratory tract achieved prevention of a viral hemorrhagic fever infection in a primate model."

(A. Bukreyev, P.E. Rollin, M.K. Tate, L. Yang, S.R. Zaki, W.J. Shieh, B.R. Murphy, P.L. Collins, A. Sanchez. 2007. Successful topical respiratory tract immunization of primates against Ebola virus. Journal of Virology, 81. 12: 6379-6388).




Bullfrogs May Serve as Hosts for E. coli O157:H7

For the first time researchers have identified American bullfrogs as potentially suitable hosts for E. coli O157:H7, a common source of food-borne illness. They report their findings in the June 2007 issue of the journal Applied and Environmental Microbiology.

Escherichia coli O157:H7 is a major food safety concern worldwide. Cattle are known reservoirs of the bacterium and researchers are now suggesting transmission to aquatic vertebrates, such as amphibians, occurs when infected cattle defecate in water sources. Infected tadpoles could then shed the pathogen and infect cattle drinking the contaminated water as well as vegetables if the water is used for irrigation.

In the study researchers orally inoculated American bullfrog tadpoles and metamorphs with E. coli O157:H7 and tested for infection after 14 days. Tadpoles, which were housed in flowthrough aquaria, did not become infected, however 54% of metamorphs tested positive after being housed in stagnant aquaria.

"Our results suggest that American bullfrog metamorphs could function as a 'spill-over' reservoir for E. coli O157:H7 and thus contribute to its persistence in aquatic environments," say the researchers. "Further, given that metamorphs are capable of dispersal, they may have a role in the epidemiology of this pathogen."

(M.J. Gray, S. Rajeev, D.L. Miller, A.C. Schmutzer, E.C. Burton, E.D. Rogers, G.J. Hickling. 2007. Preliminary evidence that American bullfrogs (Rana catesbeiana) are suitable hosts for Escherichia coli O157:H7. Applied and Environmental Microbiology, 73. 12: 4066-4068).
-end-


American Society for Microbiology

Related Ebola Virus Articles from Brightsurf:

Targeting the shell of the Ebola virus
As the world grapples with COVID-19, the Ebola virus is again raging.

New universal Ebola vaccine may fight all four virus species that infect humans
Infectious disease scientists report early development of a potential universal vaccine for Ebola viruses that preclinical tests show might neutralize all four species of these deadly viruses infecting people in recent outbreaks, mainly in Africa.

Researchers show how Ebola virus hijacks host lipids
Robert Stahelin studies some of the world's deadliest viruses. Filoviruses, including Ebola virus and Marburg virus, cause viral hemorrhagic fever with high fatality rates.

Recognise and control new variants of the deadly Ebola virus more quickly
Joint press release by the DZIF and Charité. The situation is extraordinary: there have only ever been four declarations of public health emergencies of international concern in the past and now there are two at the same time.

Investigational drugs reduce risk of death from Ebola virus disease
The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease (EVD) compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC).

Researchers learn how Ebola virus disables the body's immune defenses
A new study by researchers from The University of Texas Medical Branch at Galveston uncovered new information on why the Ebola virus can exert such catastrophic effects on the infected person.

Mutant live attenuated Ebola virus immunizes non-human primates
Inoculation with an Ebola virus that has mutations in a protein called VP35 does not cause disease and elicits protection in monkeys, researchers show Sept.

Groundbreaking study could lead to fast, simple test for Ebola virus
In a breakthrough that could lead to a simple and inexpensive test for Ebola virus disease, researchers have generated two antibodies to the deadly virus.

RIT professor develops microfluidic device to better detect Ebola virus
A faculty-researcher at Rochester Institute of technology has developed a prototype micro device with bio-sensors that can detect the deadly Ebola virus.

NEJM applying universal standards of care to Ebola virus disease
LSTM's Senior Clinical Lecturer, Dr. Shevin Jacob, is corresponding author on a perspective piece published in the New England Journal of Medicine calling for universal standards of care to be applied in relation to ebola virus disease.

Read More: Ebola Virus News and Ebola Virus Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.